Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 3/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14966126 | 0.88 | CETP (0.52) | CARM1PRMT6MAPK14CETPCHRM2 | |
| SCHEMBL22957758 | 0.85 | CHRM2 (0.51) | CARM1PRMT6CETPCHRM2CHRM1 | |
| SCHEMBL14438320 | 0.83 | MEP1B (0.48) | ROCK2ROCK1KCNB1SLC2A1DAO | |
| SCHEMBL29373647 | 0.82 | PRMT6 (0.59) | CARM1PRMT6MAPK14CETPCHRM2 | |
| SCHEMBL8348536 | 0.82 | PRMT6 (0.59) | CARM1PRMT6MAPK14CETPCHRM2 | |
| SCHEMBL22957707 | 0.82 | MEN1 (0.45) | CETPGRM2SLC2A1 | |
| SCHEMBL7805541 | 0.81 | MAPK14 (0.45) | CARM1PRMT6MAPK14CETPCHRM2 | |
| SCHEMBL2954251 | 0.80 | CASR (0.60) | CHRM2CHRM1CHRM3 | |
| SCHEMBL13125739 | 0.80 | EPHX2 (0.48) | — | |
| SCHEMBL22957820 | 0.80 | CARM1 (0.44) | CARM1PRMT6MAPK14CETPROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CHEMOCENTRYX, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11241013-B2 | Benzimidazole compounds as agricultural chemicals | REDAG CROP PROT LTD (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20210204547-A1 | BENZIMIDAZOLE COMPOUNDS AS AGRICULTURAL CHEMICALS | REDAG CROP PROT LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190134049-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9458110-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160016910-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | disclosed |
| US-9126944-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140243338-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-28 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-7459460-B2 | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | CARM1 2902/4885PRMT6 2190/4885MAPK14 1342/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | CARM1 2902/4885PRMT6 2190/4885MAPK14 1342/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | CARM1 4699/4885PRMT6 3949/4885MAPK14 3889/4885 |
| US-11241013-B2 | Benzimidazole compounds as agricultural chemicals | CYP3A4, CYP2C8, CYP2E1 | CARM1 751/4885PRMT6 1986/4885MAPK14 2222/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | CARM1 2902/4885PRMT6 2190/4885MAPK14 1342/4885 |
| US-20140243338-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | CARM1 1232/4885PRMT6 1444/4885MAPK14 136/4885 |
| US-20160016910-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | CARM1 1232/4885PRMT6 1444/4885MAPK14 136/4885 |
| US-20190134049-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CARM1 2277/4885PRMT6 1784/4885MAPK14 1603/4885 |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CCR2, PDCD1LG2, CD274 | CARM1 2277/4885PRMT6 1784/4885MAPK14 1603/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CARM1 2277/4885PRMT6 1784/4885MAPK14 1603/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | CARM1 2530/4885PRMT6 3097/4885MAPK14 1594/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | CARM1 960/4885PRMT6 585/4885MAPK14 285/4885 |
| US-20210204547-A1 | BENZIMIDAZOLE COMPOUNDS AS AGRICULTURAL CHEMICALS | CYP3A4, CYP2C8, CYP2E1 | CARM1 751/4885PRMT6 1986/4885MAPK14 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.